MAP2K7 and ovarian cancer: In preclinical studies, vaccinia virus combined with anti-PD1 therapy caused tumor reduction in glioblastoma (42), and vaccinia virus combined with MEK inhibitory therapy resulted in enhanced cytotoxicity in doxorubicin-resistant ovarian cancer (43).